Innate Pharma (IPHYF) Downgraded to “Sell” at Zacks Investment Research

Innate Pharma (OTCMKTS:IPHYF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

Innate Pharma stock opened at $6.39 on Wednesday. The firm has a market cap of $368.06 million, a PE ratio of 106.50 and a beta of 0.16. Innate Pharma has a fifty-two week low of $5.07 and a fifty-two week high of $10.40.

About Innate Pharma

Innate Pharma SA, a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils.

Featured Story: Risk Tolerance

Get a free copy of the Zacks research report on Innate Pharma (IPHYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.